United Kingdom Musculoskeletal Disorders Treatment Drugs Market By Drug Type (Analgesics, DMARDS, Corticosteroids, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies), By Drug Classification (Branded Drugs, Generic Drugs), By Region, Competition Forecast & Opportunities, 2018-2028F

United Kingdom Musculoskeletal Disorders Treatment Drugs Market is primarily going to be driven by the growing geriatric population in constituent countries of the United Kingdom, such as England, Wales, Southern Ireland, and Scotland, during the forecast period. Musculoskeletal disorders are a group of diverse conditions that affect muscles, bones, tendons, ligaments, and other supportive structures of the body. These disorders comprise long-term conditions such as back problems, gout, juvenile arthritis, rheumatoid arthritis, osteoarthritis, and osteoporosis. Some of the leading factors that increase the chances of musculoskeletal disorders in a person include improper posture, traumatic injuries, genetic disorders, systemic diseases such as arthritis, lupus, or fibromyalgia, repetitive motions of the body, and others. In the United Kingdom, over 20 million people are diagnosed with various musculoskeletal conditions such as back pain or arthritis every year. The National Health Service (NHS) of the United Kingdom is actively participating in controlling the prevalence of musculoskeletal disorders by providing quick access to specialists such as rheumatologists and orthopedic surgeons, occupational therapy, pain management clinics, and physiotherapy. Moreover, the growing demand for medications among people instead of undergoing surgeries is also a significant aspect expected to register impressive growth in the musculoskeletal disorders treatment drugs market in upcoming years. The incorporation of novel techniques in hospitals for the treatment of musculoskeletal diseases and improving the healthcare system of the United Kingdom are also other factors expected to propel the growth of the United Kingdom Musculoskeletal Disorders Treatment Drugs Market in the forecast period.

Growing Prevalence of Musculoskeletal Disorders

Musculoskeletal disorders encompass a wide range of conditions that affect several joints of the body, leading to pain, stiffness, and limited mobility. Several prominent reasons are increasing the instances of musculoskeletal disorders in the United Kingdom. Occupational hazards caused by industries that demand physical tasks, sedentary lifestyles of people including physical inactivity, genetic predisposition, and growing demographics are contributing to the emergence of musculoskeletal conditions in the country. According to the data revealed by the United Kingdom Government, it has been observed that in 2018, women reported a significantly higher prevalence of musculoskeletal conditions than men (19% compared with 14.9%). The prevalence in the English, Scottish, Welsh, and Northern Irish ethnic group was estimated to be around 19%. Moreover, rates of musculoskeletal disorders also varied by working status, with higher instances of disorders recorded in the 'retired' working status group (33.8%) and the lowest in those who were in full-time education (2.6%). Based on the scenario of 2021, certain joint disorders that dominated the health of people in the United Kingdom include osteoporosis, osteoarthritis, back pain, rheumatoid arthritis, and fibromyalgia. According to a survey conducted by BMC Health Services Research in 2022, by specialty, the greatest proportion of professionals diagnosing fibromyalgia were rheumatologists (100.0%), followed by physicians in pain medicine (83.0%) and general practitioners (69.7%). The results of the diagnosis depicted that out of 1697 respondents, 717 (42.3%) people were suffering from fibromyalgia, which accounted for the majority of adults (86.6%) followed by adolescents (12.7%). The growing prevalence rate of musculoskeletal disorders is increasing people's concern for their health. Therefore, the growing demand for drugs and treatments for the management of musculoskeletal discomfort is expected to register lucrative growth in the United Kingdom Musculoskeletal Disorders Treatment Drugs Market in the forecast period.

Increase in Geriatric Population

The growing rate of the geriatric population in developing regions of the United Kingdom is one of the predominant factors supporting market growth. This demographic shift is primarily due to factors such as improved healthcare, advancements in medical technology, and a generally higher standard of living. Currently, there are over 15.5 million people aged above 60 years, making up 23% of the United Kingdom's population. About 4 million older people (40% of people over the age of 65) have long-term disabling illnesses or disabilities. Certain musculoskeletal disorders that are found to be more prevalent among elderly people include osteoarthritis, rheumatoid arthritis, and osteoporosis. Two varieties of osteoarthritis that are common among the elderly population in England are knee osteoarthritis and hip osteoarthritis. According to the report provided by Public Health England, it has been observed that in Kensington and Chelsea, around 8,311 people aged above 45 years are suffering from knee osteoarthritis, which accounts for a male prevalence of 13.1%, followed by a female prevalence of 15.9%. Moreover, in England, a total of 5,456 people aged above 45 years were diagnosed with hip osteoarthritis, including 1,858 males (6.9%) and 3,598 females (11.9%). Some preventive and therapeutic approaches for geriatric individuals suffering from musculoskeletal disorders include the consumption of a healthy diet, medication management, regular check-ups, and others. Moreover, the growing demand for drugs depending on the specific condition and individual patient factors is also expected to register impressive growth in the United Kingdom Musculoskeletal Disorders Treatment Drugs Market in the forecast period.

Download Free Sample Report

Growing Demand for Medications

The rise in the incidences of musculoskeletal disorders has led to a growing demand for effective treatment options in the United Kingdom. The growing preference of people towards medication over surgical procedures due to certain reasons such as cost considerations, risks and complications, and efficacy of medicines in managing medical conditions is propelling the demand for drugs in the market. The choice of drug can vary depending on the age and medical conditions of individual patients. However, some of the common drugs generally consumed by people to prevent their musculoskeletal problems include Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen, naproxen, and diclofenac, Acetaminophen, Opioids, Bisphosphonates, Disease-Modifying Antirheumatic Drugs (DMARDs), and Corticosteroids. Moreover, advances in drug therapies and improvements in the properties of medicines are also influencing the growth of the United Kingdom Musculoskeletal Disorders Treatment Drugs Market. Biologic drugs, such as anti-TNF (tumor necrosis factor) agents, have revolutionized the treatment of conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in recent years. Drugs like adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade) are widely used in the UK to manage these disorders. Moreover, for the treatment of osteoporosis, common medicines prescribed for the management of this condition of weak and brittle bones include alendronate (Fosamax) and risedronate (Actonel).

Development in Healthcare Infrastructure

According to the analysis conducted by Statista in 2022, around 1,910 new hospitals were built in the UK in 2018, followed by 1,978 hospitals in 2019, 1,921 hospitals in 2020, and so on

Recent Developments

• InSeptember 2021, Novartis announced that the U.S. Food and Drug Administration(FDA) has granted fast-track designation to LNA043 for the treatment ofosteoarthritis of the knee.
• InSeptember 2020, the Janssen Pharmaceutical Companies of Johnson & Johnsonannounced that the U.S. Food and Drug Administration (FDA) has approved SIMPONIARIA (golimumab) for patients 2 years of age and older for the treatment ofactive polyarticular juvenile idiopathic arthritis (pJIA).

United Kingdom Musculoskeletal Disorders Treatment Drugs Market is segmented based on Drug Type, Route of Administration, Distribution Channel, Drug Classification, Company, and Region. In terms of drug type, the market is categorized into Analgesics, DMARDS, Corticosteroids, and Others. Based on, route of administration, the market is divided into Oral and Parenteral. On the basis of distribution channel, the market is segmented into Hospital Pharmacies, Online Providers, Drug retailers, and Retail Pharmacies. Based on drug classification, UK musculoskeletal disorders treatment drugs market is fragmented into Branded Drugs and Generic Drugs.

Market Players

GlaxoSmithKline plc., AstraZeneca PLC., Novartis Pharmaceuticals UK Ltd., Bayer plc., Johnson & Johnson Pvt. Ltd., Reckitt Benckiser Group PLC., F. Hoffmann-La Roche Ltd., Marksans Pharma Ltd.